Several long-awaited vaccines are closer to reality than most people realize. A Lyme disease vaccine could hit the market by 2026 or 2027. A tuberculosis vaccine just finished enrolling 20,000 people in a massive Phase 3 trial. Personalized cancer vaccines cut melanoma recurrence nearly in half in clinical testing. And researchers are making early but genuine progress on vaccines for HIV, Epstein-Barr virus, and universal flu protection. Here’s where things actually stand across the diseases that matter most.
Lyme Disease: Closest to Market
The Lyme disease vaccine is arguably the furthest along of any major vaccine in development. Pfizer and Valneva have completed the primary vaccination series in their Phase 3 trial (called VALOR), and participants are being monitored for Lyme disease cases through the end of the 2025 season. If the data looks good, Pfizer plans to submit for FDA approval in 2026, with a European filing happening around the same time. That puts a commercially available Lyme vaccine potentially within two years.
This matters because there hasn’t been a Lyme disease vaccine available since 2002, when a previous version was pulled from the market due to low demand and public concern. The new candidate, VLA15, works differently and targets the outer surface protein of the bacteria before it even leaves the tick. For anyone living in tick-heavy regions of the northeastern U.S. or northern Europe, this is the vaccine closest to changing daily life.
Tuberculosis: A Phase 3 Trial 11 Months Ahead of Schedule
Tuberculosis kills roughly 1.3 million people a year, and the only existing vaccine, BCG, was developed over a century ago and offers limited protection in adults. The M72/AS01E vaccine candidate, backed by the Gates Medical Research Institute, is now in a fully enrolled Phase 3 trial with approximately 20,000 participants across 54 trial sites in five countries. Enrollment finished 11 months ahead of schedule, which is unusual for a trial this large.
Earlier trials showed M72 reduced progression from latent TB infection to active disease by about half, a result that generated enormous excitement in global health. The Phase 3 trial will confirm whether that protection holds up in a much larger and more diverse population. If it does, this would be the first new TB vaccine in over a century, with enormous implications for sub-Saharan Africa and South Asia where the disease burden is heaviest.
Malaria: Already Saving Lives
Unlike most entries on this list, the malaria vaccine story is no longer about “how close.” It’s here. The R21/Matrix-M vaccine has received WHO prequalification and is already licensed in several African countries. In a Phase 3 trial of 4,644 children aged 5 to 36 months, the vaccine showed 75% efficacy at seasonal transmission sites and 68% at sites with year-round malaria, measured by time to first clinical malaria episode over 12 months. In the youngest group (5 to 17 months), efficacy reached 79% at seasonal sites.
These numbers represent a meaningful jump over the first-generation malaria vaccine, RTS,S, which showed lower efficacy in comparable trials. R21 is also cheaper to produce, which matters enormously when you’re trying to vaccinate hundreds of millions of children across sub-Saharan Africa. Rollouts are underway, and this vaccine is expected to prevent hundreds of thousands of childhood deaths over the coming decade.
Cancer Vaccines: Personalized and Promising
The most exciting development in cancer vaccines is a personalized mRNA approach that tailors each dose to a patient’s individual tumor. In a Phase 2b trial for melanoma, patients who received the personalized vaccine alongside standard immunotherapy had a 22% recurrence or death rate over roughly two years, compared to 40% in the group that received immunotherapy alone. At the 18-month mark, recurrence-free survival was 79% in the combination group versus 62% with immunotherapy alone.
The concept is straightforward: after a tumor is surgically removed, researchers sequence its DNA, identify mutations unique to that cancer, and build an mRNA vaccine that trains the immune system to hunt down any remaining cells carrying those mutations. The trial enrolled 157 patients with high-risk melanoma, and the results were strong enough that a larger Phase 3 trial is now underway. Trials are also expanding into other cancer types, including lung cancer and certain skin cancers. If Phase 3 results hold up, this could become part of standard post-surgery treatment within a few years.
HIV: Still Early, but a New Approach
An HIV vaccine has been one of the hardest problems in medicine for four decades. The virus mutates rapidly, attacks the very immune cells meant to fight it, and hides in the body in ways that make it nearly invisible to standard vaccine strategies. Dozens of candidates have failed in clinical trials over the years.
The most recent hope is VIR-1388, now in a Phase 1 trial enrolling 95 HIV-negative participants across sites in the United States and South Africa. Rather than trying to generate antibodies (the approach that has repeatedly failed), VIR-1388 is designed to train T cells to recognize HIV and prevent the virus from establishing a chronic infection. It uses a weakened version of cytomegalovirus, a common and usually harmless virus, as a delivery vehicle to get HIV vaccine material into the immune system.
Phase 1 means this is still in the safety and early immune-response stage. Even optimistic timelines put a viable HIV vaccine many years away. But the shift in strategy, from antibodies to T cells and from traditional platforms to viral vectors, represents a genuinely different scientific bet than previous attempts.
Universal Flu: One Shot to Replace Annual Vaccines
Every year, scientists essentially guess which flu strains will dominate the coming season and build a vaccine around those predictions. When they guess well, the vaccine works reasonably. When they don’t, protection drops significantly. A universal flu vaccine would target parts of the virus that stay constant across strains, eliminating the need for annual reformulation and providing broader, longer-lasting protection.
The NIH’s National Institute of Allergy and Infectious Diseases is now running an early-stage clinical trial of an mRNA-based universal flu vaccine candidate, developed through the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program. A similar vaccine from the NIH’s own Vaccine Research Center has already shown positive results in early trials. These are still Phase 1 studies, so a universal flu vaccine is likely at least five to eight years from reaching the public. But the mRNA platform, validated at unprecedented speed during the COVID-19 pandemic, has dramatically accelerated the timeline compared to where researchers thought they’d be a decade ago.
Epstein-Barr Virus: Targeting the “Mono” Virus
Epstein-Barr virus infects roughly 95% of adults worldwide, usually causing nothing more than mononucleosis (“mono”) in adolescence. But EBV has also been strongly linked to multiple sclerosis and several cancers, making a vaccine potentially far more impactful than preventing a few weeks of fatigue and sore throat.
Moderna’s mRNA-1189 is currently in a combined Phase 1/Phase 2 trial in healthy adolescents and adults aged 10 to 30. The trial is specifically focused on preventing EBV infection and infectious mononucleosis. It will take years to determine whether preventing EBV infection also reduces rates of multiple sclerosis and EBV-associated cancers, but the basic science connecting them is strong enough that researchers consider it a reasonable expectation.
Next-Generation COVID Vaccines: Nasal Sprays
Current COVID vaccines do a good job preventing severe illness but are less effective at blocking infection and transmission, partly because they generate strong immune responses in the blood but weaker ones in the nose and airways where the virus first lands. Intranasal vaccines aim to fix this by building immunity directly at the site of infection.
In preclinical studies, nasal COVID vaccines generated a three-pronged immune response: antibodies in the blood, T cell immunity, and mucosal antibodies (called IgA) in the nose and lungs. In animal models, a single nasal dose prevented infection in both the upper and lower respiratory tract. In hamster transmission studies, nasal vaccination reduced viral shedding enough to achieve complete transmission control. Several candidates are now in human trials, though none have yet reached late-stage testing. The challenge has been translating those dramatic animal results into consistent human data, a gap that has slowed several nasal vaccine programs.
RSV Vaccines: Expanding Beyond Older Adults
RSV vaccines for adults over 60 were approved in 2023, and a maternal vaccine that protects newborns through antibodies passed during pregnancy is also available. The next frontier is vaccinating infants and young children directly, which has proven more complicated than expected.
In trials of mRNA-based RSV vaccines in young infants (5 to 8 months old), researchers observed a concerning signal: more vaccinated infants progressed to severe RSV illness than those who received a placebo. In one trial cohort, 26.3% of vaccinated infants with symptomatic RSV developed severe illness, compared to 8.3% in the placebo group. This raised concerns about a phenomenon called vaccine-associated enhanced respiratory disease, where the immune response triggered by the vaccine actually worsens infection rather than preventing it. This same problem derailed RSV vaccine development in the 1960s and has made the FDA extremely cautious about pediatric RSV vaccines. For now, protecting infants relies on maternal vaccination and monoclonal antibody injections given after birth, while researchers work to develop formulations that are safe for the youngest age groups.